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1 |  INTRODUCTION AND 
BACKGROUND
Adipose tissue is a highly dynamic tissue that functions as 
the primary energy reservoir in the human body and can be 
viewed as an “organ,” dispersed at discrete locations in the 
body referred to as depots. Adipocytes comprise approxi-
mately 90% of the tissue volume and are traditionally divided 
into two morphologically and functionally distinct subtypes 
referred to as white and brown adipocytes.1 White adipose 
Received: 29 October 2020 | Revised: 16 February 2021 | Accepted: 18 February 2021
DOI: 10.1111/bcpt.13575  
O R I G I N A L  A R T I C L E
Subcutaneous adipose tissue composition and function are 
unaffected by liraglutide- induced weight loss in adults with type 1 
diabetes
Anne- Marie Wegeberg1,2  |   Theresa Meldgaard1  |   Amanda Bæk3 |    
Asbjørn Mohr Drewes1,2,4  |   Mogens Vyberg2  |   Niels Jessen3  |    
Birgitte Brock5  |   Christina Brock1,2,4
1Mech- Sense, Department of 
Gastroenterology & Hepatology, Aalborg 
University Hospital, Aalborg, Denmark
2Clinical Institute, Aalborg University, 
Aalborg, Denmark
3The Research Laboratory for Biochemical 
Pathology, Department of Clinical 
Medicine, Aarhus University Hospital, 
Aarhus, Denmark
4Steno Diabetes Center North Denmark, 
Aalborg University Hospital and Clinical 
Institute, Aalborg University, Aalborg, Denmark
5Steno Diabetes Center Copenhagen, 
Aarhus, Denmark
Correspondence
Christina Brock, Mech- Sense, Department 
of Gastroenterology and Hepatology, 
Aalborg University Hospital, Mølleparkvej 
4, 9000 Aalborg, Denmark.
Email: christina.brock@rn.dk
Funding information
The Novo Nordisk Scandinavia AS and 
Empowering Industry and Research (EIR), 
Northern Jutland, supported this investigator- 
initiated and investigator- driven trial. CB 
received funding from the Talent Management 
Programme, Aalborg University.
Abstract
Adipose tissue is the primary energy reservoir of the human body, which also pos-
sesses endocrine functions. The glucagon- like peptide agonist liraglutide produces 
weight loss, although the specific effects on adipose tissue are unknown. We aimed 
to characterize the white adipose tissue composition and pericellular fibrosis of sub-
cutaneous adipose tissue in response to liraglutide treatment. Furthermore, we ex-
plored the level of circulating free fatty acids, cluster of differentiation 163 (CD163) 
macrophage marker, leptin and adiponectin. Thirty- nine adults with type 1 diabetes 
and polyneuropathy were randomly assigned to 26 weeks of liraglutide or placebo 
treatment. Biopsies of subcutaneous tissue were formalin- fixed stained with picro-
sirius red to visualize collagen or immunohistochemically stained for CD163. Serum 
concentrations of free fatty acids, CD163, leptin and adiponectin were assessed with 
immunoassays or multiplex panels. In comparison with placebo, liraglutide induced 
weight loss (3.38 kg, 95% CI −5.29; −1.48, P < 0.001), but did not cause any differ-
ences in cell size, distribution of CD163- positive cells, pericellular fibrosis and serum 
levels of free fatty acids, CD163, leptin or adiponectin (all P < 0.1). Additionally, 
no associations between weight loss, cell size and serum markers were found (all 
P > 0.08). In conclusion, despite liraglutide's effect on weight loss, sustained altera-
tions in subcutaneous adipose tissue did not seem to appear.
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tissue possesses endocrine functions and secretes adipokines, 
including leptin and adiponectin, which regulate appetite and 
energy metabolism. Furthermore, they are involved in sys-
temic metabolic homeostasis and redistribution of adipose 
tissue, while the less abundant brown adipocytes are rich in 
mitochondria and thus metabolically active.2,3
Liraglutide is a GLP- 1 agonist that shares the same phar-
macological effects as native GLP- 1.4 GLP- 1’s primary ef-
fect is reducing plasma glucose concentrations by stimulating 
insulin secretion from pancreatic β- cells and depresses glu-
cagon secretion. Liraglutide is known to improve glycaemic 
control, induce body- weight loss and decrease exogenous in-
sulin requirement when used as an adjunct to insulin in type 1 
diabetes.5 In addition, in vitro and in vivo studies have consis-
tently shown that GLP- 1 analogues possess antioxidative and 
anti- inflammatory effects, putatively mediated alterations in 
monocyte function, diminished macrophage infiltrations and 
consequently inhibition of pro- inflammatory pathways.6,7
Finally, GLP- 1 receptors are expressed in adipose tis-
sues8 and are thus believed to play a role in lipid metabo-
lism. Liraglutide- induced weight loss is known to affect all 
adipose depots in the body,9- 12 though the underlying mech-
anisms are not fully elucidated.10 Rodent studies suggest that 
liraglutide and similar GLP- 1 agonists may not only induce 
weight loss, with a reduction in whole- body fat mass but con-
comitantly reduce white adipocyte cell size, suggestive of im-
proved metabolic function.13,14 Taken together, activation of 
the GLP- 1 axis impacts the composition of the white adipose 
tissue by  inducing changes in (a) cell size, (b) the relative 
degree of connective tissue to cell size and (c) the presence 
of inflammatory cells. There are, however, no reports on the 
GLP- 1- induced fat- reducing mechanisms in human beings.
Thus, we hypothesize that weight loss caused by liraglu-
tide administration will influence the composition and func-
tion of subcutaneous adipose tissue independent of glucose 
metabolism. We aimed to characterize the white adipose cell 
size and grade the relative pericellular fibrosis in the subcuta-
neous adipose tissue in response to liraglutide/placebo treat-
ment. Secondly, we explored the level of circulating free fatty 
acids, the macrophage marker sCD163, the hormones leptin 
and adiponectin in response to liraglutide/placebo treatment, 
and if they were associated with weight loss and cell size.
2 |  MATERIAL AND METHODS
2.1 | Study design and patient selection
These data are secondary analysis deriving from a larger, 
randomized, double- blinded single- centre, parallel- group, 
placebo- controlled prospective clinical trial investigating the 
neuroprotective and anti- inflammatory effect of liraglutide 
for the treatment of distal symmetrical polyneuropathy.15 
The study was conducted in accordance with the Basic & 
Clinical Pharmacology & Toxicology policy for experimen-
tal and clinical studies.16 Ethical approval was granted by 
The North Denmark Region Committee on Health Research 
Ethics, Denmark (N- 20130077), and all participants gave 
written informed consent before entry. The study was regis-
tered in public databases (EUDRA CT (ref 2013- 004375- 12) 
and clinicaltrials.gov (ref NCT02138045) and performed in 
accordance with the International Council for Harmonization 
Good Clinical Practice and the Declaration of Helsinki. The 
experiment was conducted between June 2014 and January 
2017 at Aalborg University Hospital.
Potential participants with type 1 diabetes were recruited 
at the Department of Endocrinology. Due to the primary out-
come of the RCT, participants were included based on nerve 
conduction tests to diagnose distal symmetrical polyneuropathy 
(DSPN) according to the Toronto criteria.17 Additional inclusion 
criteria were age above 18 years, a verified diagnosis of type 
1 diabetes for a minimum of 2 years: (glycated haemoglobin 
[HbA1c] ≥6.5% [>48 mmol/mol]), stable hyperglycaemic med-
ication ensuring that participants as a minimum had received 
the given treatment (long- acting and fast- acting insulin or insu-
lin pump with dosing adjustments according to regimens) for at 
least 3 months before study entry, body mass index >22 kg/m2 
and written consent. Exclusion criteria included type 2 diabetes, 
other neurological disorders than DSPN, estimated glomeru-
lar filtration rate < 60 mL/min/1.73 m2; calcitonin > 25 ng/L, 
HbA1c level <6.5%, use of GLP- 1 agonist, or DPP- 4 inhibitors.
Treatments appeared identical and were randomly as-
signed 1:1 liraglutide or placebo in blocks of eight from a 
randomization list generated by the drug supplier. The inter-
vention was titrated over six weeks to a dose between 1.2 and 
1.8 mg/d, depending on individual tolerability, and continued 
for further 26  weeks. In case of drop- outs or withdrawals, 
a new participant was recruited to receive the same treat-
ment as the drop- out in a mirrored randomized fashion. The 
subcutaneous biopsies were collected at baseline and after 
26 weeks of intervention, and a venous fasting serum sample 
was obtained from an antecubital vein.
2.2 | Biopsies and histological techniques
Local anaesthetic (xylocaine, lidocaine HCl 20  mg/mL) was 
injected into the subcutaneous paraumbilical abdominal area. 
When the analgesic effect was obtained after 10- 15 minutes, 
the adipose tissue biopsies were obtained by moderate vacuum 
suction performed with a syringe (14G*31/8”, 2.1*80 mm) and 
plunger (50 mL). The adipose tissue was flushed three times 
with 0.9% NaCl to remove erythrocytes before snap- freezing in 
liquid N2. Frozen adipose tissue was transferred to 1- mL cryo 
tubes and stored at −80°C until all samples collectively could 
be processed further. Frozen biopsies were fixed in 4% formalin 
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and embedded in paraffin, and 5- µm sections were cut accord-
ing to standard procedures. Immunohistochemical staining with 
antibody against CD163 was performed to evaluate adipose 
tissue inflammation as assessed by the presence of CD163- 
positive macrophages. For visualization of collagen in tissue 
sections, picrosirius red staining was performed. Preparation 
of biopsies for histological assessment was performed at the 
Institute of Pathology, Aalborg University Hospital. The sec-
tions were blinded with regard to patient and treatment status.
2.3 | Image acquisition
An automated slide scanner (Hamamatsu Photonics) was 
used to acquire full- slide light microscopy 20× magnifica-
tion scans (ndpi files) of the biopsies. Images (TIFF files) 
of the biopsies were generated using the export function in 
NanoZoomer viewer (Hamamatsu Photonics). The open- 
source platform for biological image analysis (Fiji is Just) 
ImageJ 2.2.0 was applied for image analysis. Non- tissue 
areas were cropped from images using the freehand selection 
tool in preparation for image analysis. Furthermore, blood 
vessels and streaks of connective tissue were cropped from 
images applied for the assessment of pericellular fibrosis.
2.4 | Image analysis
2.4.1 | Quantification of adipocyte size
For assessment of cell size (µm2), cropped images of picro-
sirius red- stained tissue were analysed with the ImageJ pl-
ugin Adiposoft 1.14 (Adiposoft, CIMA).18 Settings: manual 
mode; output units: microns; one image analysis. Calibration: 
micrometre per pixel: 0.457 (calculated from measurements 
of scalebar in un- cropped 20x images); minimum diameter: 
20 µm; maximum diameter: 150 µm. Using the manual edition 
mode, outputs were cleaned by removing faulty counts such as 
damaged cells, structures resembling cells and cells with ≥2 
counts inside or shape covering less than approximately 80% 
of the area. Prior to statistical analysis, biopsies were scored 
from 0 to 3 concerning quality, and those with a score of 0 
were excluded to ensure data quality. Representative images 
of biopsies before and after treatment are shown in Figure 1.
2.4.2 | Assessment of inflammation and 
CD163- positive cells
Tissue sections were immunohistochemically stained with 
antibodies specific to the surface marker CD163 to identify 
cells of monocyte/macrophage lineage,19 and images were 
acquired. An image of a representative area at 10x magni-
fication of anti- CD163 stained sections for each biopsy was 
assessed by visual inspection. Each biopsy was assigned a 
score for the frequency of CD163- positive cells from the fol-
lowing arbitrary scale (score: estimated number of positive 
cells): 0: ≤ 50; 1:50> and <130; 2: ≥130.
2.4.3 | Quantification of pericellular fibrosis
The red stain level in cropped images of picrosirius red- 
stained tissue was quantified by running a segmentation macro 
in batch mode in ImageJ to assess pericellular fibrosis. The 
macro is based on a protocol for quantification of stained liver 
tissue20 and involves six steps. The ratio of the red- stained 
area (step 4) to the full tissue area (step 6) was calculated.
2.5 | Clinical biochemistry
Serum concentrations of non- esterified free fatty acids 
(FFA) were assessed by the enzymatic colorimetric assay 
NEFA- HR(2) (Wako Chemicals). Serum concentrations of 
the specific macrophage marker sCD163 were analysed by 
enzyme- linked immunosorbent assay at the Department of 
Clinical Biochemistry, Aarhus University Hospital. Serum 
concentrations of adiponectin and leptin were determined 
by Multiplex Luminex assay using the Abundant Serum 
F I G U R E  1  Composition of white adipose tissue: depicts representative images of abdominal subcutaneous adipose biopsies before (A) and 
after (B) treatment with liraglutide. Collagen surrounding the adipocytes is stained with picrosirius red staining and analysed under non- polarized 
light. Scale bar (−) represents 100 µm
A B
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Markers 26- Plex Human ProcartaPlex™ Panel at Steno 
Diabetes Center Copenhagen. Serum levels of triglycerides, 
total cholesterol, HDL cholesterol and LDL cholesterol were 
analysed according to standard procedures by the Department 
of Biochemistry, Aarhus University Hospital.
2.6 | Statistical analysis
Normality of the data was assessed using the Shapiro- Wilk 
test of normality. Normally distributed data are expressed 
as mean ± SD or +SEM, and non- normally distributed data 
are expressed as median (IQR). Analyses were performed 
using Stata Statistical Software: Release 15. (StataCorp. 
2017: StataCorp LLC) with a significance level of P <0.05. 
Differences in treatment groups were assessed using a two- 
sample t test for continuous data, a chi- squared test for 
categorical valuables and a Mann- Whitney U test for non- 
parametric data. Associations between weight or cell area 
and serum markers were calculated using simple linear re-
gressions and presented as a coefficients plot.
3 |  RESULTS
3.1 | Demographics
Forty- eight participants were randomized, 9 of whom with-
drew from the study due to adverse effects (7/9: severe 
nausea; 5/9: vomiting; 3/9: reflux; 3/9: decreased appetite). 
Consequently, 19 participants randomized to liraglutide and 
20 to placebo completed the trial. Demographics are shown 
in Table 1. There were no differences in the demographics, 
except that the number of participants who received long- 
acting insulin was higher in the liraglutide group (P = 0.04); 
however, the doses were similar.
3.2 | Weight loss
Liraglutide treatment resulted in a mean weight reduction of 
3.38 kg (95% CI − 5.29; −1.48, P < 0.001) compared to pla-
cebo.15 The absolute weight loss for the liraglutide and pla-
cebo group were 3.95 kg (95%CI −5.31; −2.59) and 0.55 kg 
(95%CI −2.17;1.07), respectively. Median (Q1- Q4) weight 
pre- and post- intervention are shown in Table 2.
3.3 | Subcutaneous adipose cell size and 
pericellular fibrosis
Liraglutide did not induce a difference in the median cell 
size in comparison with placebo (Δ900 µm2 vs Δ441 µm2; 
P = 0.42) (Table 2). Adipocyte size in the upper (Q4) and 
lower (Q1) quartiles was assessed separately. Liraglutide did 
not induce a difference in cell size of the upper quartile Q4 
(Δ629 µm2 vs Δ- 409 µm2; P = 0.56), but it slightly increased 
cell size in the lower quartile Q1 (Δ682 µm2 vs Δ81 µm2; 
P = 0.04) in comparison with placebo. Representative images 








Sex (male) 17/89% 14/70% 0.13
Age (years) 51 (10) 50 (8) 0.66
Body mass index 
(kg/m2)
30 (5) 29 (4) 0.62
Diabetes duration 
(years)
32 (11) 32 (7) 0.97
Haemoglobin A1c 
(mmol/mol)






75 (68- 87) 73 (69- 78) 0.44
Systolic blood 
pressure (mmHg)
144 (16) 138 (12) 0.21
Diastolic blood 
pressure (mmHg)
78 (9) 79 (9) 0.70
Medication
Fast- acting insulin 
(yes)
17/89% 13/65% 0.07




Dose (IE) 24 (22;30) 33 (20;40) 0.48
Insulin pump (yes) 2/11% 7/35% 0.07
Statins (yes) 8/42% 9/47% 0.74
Diuretics (yes) 2/11% 3/15% 0.68















Note: Data are presented as mean (standard deviation), median (Q2- Q3) or 
number/percentage.
Data have previously reported by Brock et al 2019.15
Italic indicates significant value.
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of abdominal subcutaneous adipose tissue biopsies before 
and after treatment are depicted in Figure 1.
Liraglutide did not induce any differences in the relative 
pericellular fibrosis (Δ- 0.1% vs Δ- 0.2%; P = 0.94).
3.4 | Biochemical and hormonal effects
Liraglutide did not induce any differences in the abundance 
of CD163- positive cells (Δ- 4.7  ±  32.8 vs Δ- 10  ±  32.5, 
P  =  0.19) in comparison with placebo. Representative im-
ages of sections from before and after liraglutide treatment 
are presented in Figure 2A and B, respectively.
Liraglutide did not induce any differences in the serum 
level of free fatty acids (Δ- 0.1 vs Δ0.0, P = 0.38), CD163 (Δ- 
0.1 vs Δ0.0 mg/L, P = 0.17), leptin (Δ- 0.4 vs Δ- 1.8 ng/mL, 
P = 0.59) or adiponectin (Δ2.0 vs Δ0.2 ng/mL; P = 0.99), 
see Table 2.
There were no associations between weight loss or cell 
size and serum markers (P > 0.08). A representation of the 
associations has been plotted as coefficient plots in Figure 3.
4 |  DISCUSSION
Twenty- six weeks of treatment with liraglutide induced 
weight loss, which confirms compliance to the protocol. The 
weight loss was not associated with subcutaneous adipose 
cell size, pericellular fibrosis or CD163- positive macrophage 
infiltration. Neither did liraglutide induce changes in the sys-
temic level of circulating free fatty acids, the macrophage 
marker sCD163, or the adipokines leptin and adiponectin 
involved in systemic metabolic homeostasis. Mechanism- 
related parameters such as insulin utility were not affected,15 
despite the fact that glucagon induces gluconeogenesis. We 
believe that this exposes the complexity of different path-
ways involved in glucose kinetics.21
The abundant white adipocytes primarily store and mo-
bilize fatty acids, such as triglycerides, as energy supply, 
and can broadly be classified as subcutaneous or visceral 
depots. The subcutaneous depots are the largest and account 
for approximately 80% of the body fat in normal weight 
individuals.22 Several human studies have documented the 
weight loss effect of liraglutide based on its suppression of 
appetite23- 25; for example, Vilsbøl et al reported in a meta- 
analysis26 an estimated weighted mean reduction of 2.9 kg 
after GLP- 1 administration. The induced weight loss in 
the current study of 3.4 kg confirms patient compliance to 
the protocol. Multiple studies9- 11 have quantified the mass 
and size of different adipose tissues following liraglutide 
administration, using imaging methods like computerized 
tomography, ultrasound or magnetic resonance imaging, to 
assess the adipose thickness of the area. However, these 
studies have reported contradictory results, including re-
ductions in either of or both the subcutaneous and visceral 
adipose tissues. One of the potential mechanisms involved 
in white adipose redistribution could be mediated through 
the autonomic nervous system. In support of this, Kreier 
et al27 showed that the sympathetic and parasympathetic 
branches, respectively, exert a catabolic and anabolic effect 
on adipose tissues. Thus, it has been suggested that liraglu-
tide alters adipose morphology through its action on the 
autonomic nervous system.11 Moreover, it has been sug-
gested that liraglutide affects the lipogenesis: lipolysis ratio 
through GLP- 1 receptors in the adipose tissue.8,11 In rats, 
such a reduction in fat mass in response to GLP- 1 activation 
was associated with reduced adipocyte size.28 Therefore, 
we anticipated a similar decrease in subcutaneous adipo-
cytes cell size, but no differences in cellular composition 
were shown between liraglutide and placebo administration 
in the current study. This finding could be explained by a 
more substantial loss of adipose mass in visceral adipose 
tissues29 or related to the methodology, where the biopsy— 
due to its limited location and vulnerable nature— may not 
represent the subcutaneous layer as a whole. In a cohort 
of overweight or obese adults with type 1 diabetes, sys-
temic effects of 26 weeks of liraglutide treatments showed 
increased lipolysis in the subcutaneous tissue sample, al-
beit MRI scans showed a primary fat mass reduction in the 
visceral adipose tissues.30 Though no changes in adipocyte 
sizes were shown in this study, changes in the underlying 
metabolic mechanisms, for example lipolysis, may still 
have been present. Administration of GLP- 1 in an ob/ob 
mouse model of diabetes reduced the inflammatory level 
and oxidative stress in adipocytes and macrophages, which 
collectively improved insulin sensitivity.14 Furthermore, 
studies in obese mice have shown that GLP- 1 inhibits M1 
and M2 macrophage infiltration and inflammation.14,31 
F I G U R E  2  Assessment of systemic 
inflammation in adipose tissue: depicts 
immunohistochemical stained CD163- 
positive cells in subcutaneous adipose tissue 
before (A) and after (B) treatment with 
liraglutide. Scale bar (−) represents 100 µm
A B
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The relative presence of pericellular fibrosis was nega-
tively associated with adipocyte cell size and commonly 
associated with adipose tissue inflammation and fat mass 
loss.32 Moreover, an in vitro study showed that the GLP- 1 
agonist exendin- 4 has promoted the up- regulation of ad-
iponectin levels in adipocytes by preventing the produc-
tion of inflammatory adipokines.33 However, we could not 
document differences in numbers of CD163+ M2 macro-
phages or the relative pericellular fibrosis in our human 
subcutaneous adipose biopsies in response to 26 weeks of 
liraglutide treatment. Research within metabolism research 
has established that the adipocytes are central in regulation 
of systemic nutrient and energy homeostasis. In line with 
that, white adipose tissue possesses endocrine functions 
and secretes adipokines, including leptin and adiponectin. 
Previous reports have shown that systemic levels of leptin 
were independently associated with fat cell size and adipose 
tissue mass.34 In addition, a reduction in cell size, which oc-
curs during weight loss, has been associated with increases 
in circulating adiponectin.35- 37 Our relatively small dataset 
could not support this. Leptin interacts with pathways in 
the central nervous system and through direct peripheral 
mechanisms involved in energy expenditure. Moreover, it 
regulates energy status and metabolism through interac-
tions with insulin, glucagon, the insulin- like growth fac-
tors, growth hormone and glucocorticoids.38 The role of 
leptin in hepatic gluconeogenesis shows controversies, and 
both promotion and suppression are shown.39- 41
In contrast, adiponectin inhibits hepatic gluconeogenesis 
and thereby depresses hepatic glucose production and im-
proves glycaemia.42,43 Taken together, the induced weight loss 
did not influence the “adipose function.” Measures of serum 
F I G U R E  3  Association between 
weight or cell size and serum markers 
represented as coefficients plots. The plot 
depicts the associations between weight 
(upper) or cell area (lower) serum markers. 
The different serum markers (coefficients) 
are placed on the y- axis, and the estimates 
and their confidence intervals are plotted 
along the x- axis
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levels of free fatty acids, triglycerides, sCD163, leptin and 
adiponectin could potentially have served as biomarkers for 
changes in the subcutaneous adipose composition, as leptin 
and adiponectin are known to associate with subcutaneous ad-
ipose morphology, and CD163 is a marker of inflammation.
The lack of effect of liraglutide on the subcutaneous 
white adipose cell size and macrophage infiltration may 
result from multiple factors. The full effect of liraglutide 
demands regulation through the autonomic nervous system. 
The fact that all our participants suffered from polyneurop-
athy may have prevented this mechanism fully or partially.11 
However, as GLP- 1 receptors are expressed within the ad-
ipose tissue, we expected a direct effect of the activated 
GLP- 1 axis8,11 mediated through neuronal control. Thus, 
diabetic neuropathy may provide a possible explanation of 
denervated adipose tissue, which could serve as a model for 
adipose function, including measurement of adipokines.
The strength of this human study is the randomized, 
double- blinded design; however, this study is based on sec-
ondary analysis and is not without limitations. Firstly, the 
fragile nature of adipose tissue in the biopsies has made the 
work challenging due to the variable quality of the biop-
sies, and only one slide per biopsy was analysed. Secondly, 
the white adipose tissue composition analysis provides 
novel insight as fat biopsies hitherto primarily have been 
used for protein expression in, for example, Western blot-
ting. However, interpretation of CD163- positive cells must 
be done with caution because evaluation may have been 
prone to subjective bias due to the non- automated method. 
Additionally, we investigated most of the relating factors 
in the serum, which may provide a proxy for actual effects. 
Thirdly, these subcutaneous adipose- specific results should 
be interpreted cautiously as other adipose depots, for exam-
ple visceral fat, vary in cellular composition, metabolism, 
innervation, vascularisation and endocrine output. Thus, 
the obtained weight loss in response to liraglutide must 
have induced more significant effects in other adipose tis-
sue depots, which may not have been detectable with imag-
ing methods. Additionally, the evaluation of fibrosis with 
picrosirius red staining was analysed under non- polarized 
light, a method that may be suboptimal, and thus, these 
results should be interpreted with caution. Finally, it is 
essential to emphasize that this study was carried out in 
type 1 diabetes. Therefore, the analysed anti- inflammatory 
effect was independent of glucose metabolism, in contrast 
to models, including metabolically induced inflammation 
in obesity.
5 |  CONCLUSION
We could not demonstrate sustained alterations in the sub-
cutaneous adipose tissue composition or characteristics in 
response to 26 weeks of liraglutide intervention resulting in 
weight loss. Consequently, the effect of liraglutide on weight 
loss is believed to be more pronounced in the visceral fat 
mass. These results provide the basis for further studies into 
the mechanistic effects of liraglutide on weight loss.
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